



## Clinical trial results:

**A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment**

### Summary

EudraCT number	2013-000762-11
Trial protocol	BE IT ES DE GB NL
Global end of trial date	15 January 2024

### Results information

Result version number	v1 (current)
This version publication date	18 June 2026
First version publication date	18 June 2026

### Trial information

#### Trial identification

Sponsor protocol code	62113-55115
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01979393
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	European Organisation for Research and Treatment of Cancer (EORTC)
Sponsor organisation address	Avenue Emmanuel Mounier 83/11, Brussels , Belgium, 1200
Public contact	Clinical Operations Department, European Organisation for Research and Treatment of Cancer (EORTC), +32 27741035, regulatory@eortc.be
Scientific contact	Clinical Operations Department, European Organisation for Research and Treatment of Cancer (EORTC), +32 27741035, regulatory@eortc.be

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 December 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 January 2024
Global end of trial reached?	Yes
Global end of trial date	15 January 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of the trial is to assess, in High Grade Undifferentiated Uterine Sarcoma (HUGS), the activity (PFS at 4 months) of maintenance treatment with cabozantinib when compared with placebo after clinical benefit from standard chemotherapy (doxorubicin +/- ifosfamide) (given as an adjuvant treatment after curative surgery, or for locally advanced or metastatic disease).

Protection of trial subjects:

Specific measures to protect trial subjects were specified in the protocol. The study was conducted in accordance with the Declaration of Helsinki and/or applicable national laws and regulations, whichever provided the greatest protection to the patient. The trial was also conducted in compliance with the ICH Harmonized Tripartite Guideline on Good Clinical Practice (ICH-GCP). In addition, approval from the competent ethics committee(s), as required by national legislation, was mandatory prior to study initiation to ensure ethical oversight and participant safety.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 August 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 7
Country: Number of subjects enrolled	United Kingdom: 23
Country: Number of subjects enrolled	Netherlands: 4
Country: Number of subjects enrolled	France: 20
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Italy: 4
Worldwide total number of subjects	59
EEA total number of subjects	36

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	49
From 65 to 84 years	10
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study closed registration on 30 June 2021 and closed randomization on 18 November 2021. The total accrual duration from first registration to last randomization was 6.8 years (81.5 months).

### Pre-assignment

Screening details:

The screening period was from 4 weeks before the initiation and no later than 12 weeks after the first dose administration of first line treatment. This screening step allows timely central histological review.

### Period 1

Period 1 title	Randomized (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Data analyst, Assessor

Blinding implementation details:

Blinding of treatment allocation was achieved through the use of a "treatment box" system managed by EORTC Headquarters. Following randomization, study drugs were packaged in identical boxes labelled only with a unique number or code, without indicating treatment identity. The randomization program dynamically assigned treatment based on the minimization algorithm, taking into account previously randomized patients and protocol-defined stratification factors.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cabozantinib

Arm description:

Patients randomized to cabozantinib arm will receive cabozantinib orally at a (starting) dose of 60 mg once daily.

Cabozatinib treatment will start at least three weeks after the end of the doxorubicin based regimen.

Arm type	Experimental
Investigational medicinal product name	Cabozantinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

60 mg once daily

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Patients randomized to the placebo arm will receive a placebo tablet once daily.

Treatment will start at least three weeks after the end of the doxorubicin based regimen.

Arm type	Placebo
Investigational medicinal product name	Cabozantinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

60 mg once daily

<b>Number of subjects in period 1</b>	Cabozantinib	Placebo
Started	30	29
Completed	29	27
Not completed	1	2
Lost to follow-up	1	-
Due to progressive disease	-	2

## Baseline characteristics

### Reporting groups

Reporting group title	Cabozantinib
-----------------------	--------------

Reporting group description:

Patients randomized to cabozantinib arm will receive cabozantinib orally at a (starting) dose of 60 mg once daily.

Cabozantinib treatment will start at least three weeks after the end of the doxorubicin based regimen.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Patients randomized to the placebo arm will receive a placebo tablet once daily.

Treatment will start at least three weeks after the end of the doxorubicin based regimen.

Reporting group values	Cabozantinib	Placebo	Total
Number of subjects	30	29	59
Age categorical			
Age groups in the ITT population			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	27	22	49
From 65-84 years	3	7	10
85 years and over	0	0	0
Age continuous			
Age at randomization			
Units: years			
median	56.5	57	
full range (min-max)	41 to 81	25 to 73	-
Gender categorical			
Units: Subjects			
Female	30	29	59
Male	0	0	0
Performance status			
WHO/ECOG Performance status			
Units: Subjects			
Performance status of 0	15	17	32
Performance status 1	14	12	26
Missing performance status	1	0	1

## End points

### End points reporting groups

Reporting group title	Cabozantinib
Reporting group description: Patients randomized to cabozantinib arm will receive cabozantinib orally at a (starting) dose of 60 mg once daily. Cabozatinib treatment will start at least three weeks after the end of the doxorubicin based regimen.	
Reporting group title	Placebo
Reporting group description: Patients randomized to the placebo arm will receive a placebo tablet once daily. Treatment will start at least three weeks after the end of the doxorubicin based regimen.	

### Primary: PFS rate at 4 months

End point title	PFS rate at 4 months
End point description: Progression free survival is defined as the time between the date of randomization and the date of disease progression or death, whichever comes first. Patients alive and free of progression prior to the clinical cut-off date are censored at the date of the most recent assessment.	
End point type	Primary
End point timeframe: Within 4 months from the date of randomization	

End point values	Cabozantinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	29		
Units: patients				
Number of patients alive without PD at 4 months	13	12		

### Statistical analyses

Statistical analysis title	Primary analysis
Statistical analysis description: The superiority of the cabozantinib arm against the placebo arm will be tested for PFS rate at 4 months using a 1-sided stratified Fisher exact test (Ref. 33) at the 15% significance level. The estimate of the 85% one-sided CI for the proportion of interest will be computed on the basis of the exact binomial distribution. The estimate of the difference between the binary proportions of the two treatment arms and the associated CI will be computed as well.	
Comparison groups	Cabozantinib v Placebo

Number of subjects included in analysis	59
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.544 <sup>[1]</sup>
Method	Fisher exact
Parameter estimate	Difference in PFS rate at 4 months
Point estimate	2
Confidence interval	
level	Other: 70 %
sides	1-sided
lower limit	-12.2

Notes:

[1] - One-sided p-value based on Fisher's exact test

## Secondary: progression free survival (PFS)

End point title	progression free survival (PFS)
-----------------	---------------------------------

End point description:

Progression free survival is defined as the time between the date of randomization and the date of disease progression or death, whichever comes first. Patients alive and free of progression prior to the clinical cut-off date are censored at the date of the most recent assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Between the date of randomization and the date of disease progression or death, whichever comes first.

End point values	Cabozantinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	29		
Units: % of patients alive with PD				
median (confidence interval 95%)				
Median PFS	3.7 (1.9 to 8.1)	3.7 (2.0 to 5.6)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall survival (OS)

End point title	Overall survival (OS)
-----------------	-----------------------

End point description:

Overall survival (OS) will be measured from the date of randomization until the date of death. Patients alive at the time of analysis will be censored on the last date they were known to be alive.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until the date of death



<b>End point values</b>	Cabozantinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	29		
Units: % of patients alive				
number (confidence interval 95%)				
OS estimate at 12 months	66.8 (45.6 to 81.3)	85.9 (66.7 to 94.5)		

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected on a CRF as soon as they are observed

Adverse event reporting additional description:

This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	12
--------------------	----

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group title	Cabozantinib
-----------------------	--------------

Reporting group description: -

Serious adverse events	Placebo	Cabozantinib	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 27 (0.00%)	0 / 29 (0.00%)	
number of deaths (all causes)	15	12	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Placebo	Cabozantinib	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 27 (92.59%)	28 / 29 (96.55%)	
Vascular disorders			
FLUSHING			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
HEMATOMA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	

<p><b>HYPERTENSION</b></p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>15 / 27 (55.56%)</p> <p>61</p>	<p>23 / 29 (79.31%)</p> <p>61</p>	
<p><b>HYPOTENSION</b></p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>1</p>	<p>1 / 29 (3.45%)</p> <p>1</p>	
<p><b>LYMPHEDEMA</b></p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p>	<p>1 / 29 (3.45%)</p> <p>1</p>	
<p><b>PHLEBITIS</b></p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p>	<p>1 / 29 (3.45%)</p> <p>1</p>	
<p><b>THROMBOEMBOLIC EVENT</b></p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p>	<p>3 / 29 (10.34%)</p> <p>3</p>	
<p><b>General disorders and administration site conditions</b></p> <p><b>CHILLS</b></p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p><b>EDEMA LIMBS</b></p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p><b>FATIGUE</b></p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p><b>FEVER</b></p> <p>alternative dictionary used:</p>	<p>1 / 27 (3.70%)</p> <p>2</p> <p>1 / 27 (3.70%)</p> <p>1</p> <p>15 / 27 (55.56%)</p> <p>26</p>	<p>0 / 29 (0.00%)</p> <p>0</p> <p>1 / 29 (3.45%)</p> <p>1</p> <p>20 / 29 (68.97%)</p> <p>27</p>	

MedDRA 19			
subjects affected / exposed	2 / 27 (7.41%)	2 / 29 (6.90%)	
occurrences (all)	2	2	
FLU LIKE SYMPTOMS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	1	
HYPOTHERMIA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	2	
IRRITABILITY			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
MALAISE			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
PAIN			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	2 / 27 (7.41%)	0 / 29 (0.00%)	
occurrences (all)	2	0	
Immune system disorders			
SERUM SICKNESS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
Reproductive system and breast disorders			
PELVIC PAIN			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	1	
UTERINE HAEMORRHAGE			
alternative dictionary used: MedDRA 19			

subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
VAGINAL DISCHARGE			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	1	
Respiratory, thoracic and mediastinal disorders			
COUGH			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	2 / 27 (7.41%)	0 / 29 (0.00%)	
occurrences (all)	2	0	
DYSPNEA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	3 / 29 (10.34%)	
occurrences (all)	1	3	
EPISTAXIS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	1	
LARYNGEAL DISCOMFORT			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
HOARSENESS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	1	
HICCUPS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
PLEURAL EFFUSION			
alternative dictionary used: MedDRA 19			

subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	1	
NASAL MUCOSITIS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
MUCOSITIS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
RHINORRHOEA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
RUNNY NOSE			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	2 / 29 (6.90%)	
occurrences (all)	1	2	
VOICE ALTERATION			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	3 / 27 (11.11%)	2 / 29 (6.90%)	
occurrences (all)	3	2	
SORE THROAT			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
SORE NOSE			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	2	
Psychiatric disorders			
DEPRESSION			
alternative dictionary used: MedDRA 19			

subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 29 (3.45%) 1	
INSOMNIA alternative dictionary used: MedDRA 19 subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 29 (3.45%) 1	
Investigations CPK INCREASED alternative dictionary used: MedDRA 19 subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 2	0 / 29 (0.00%) 0	
NEUTROPHIL COUNT DECREASED alternative dictionary used: MedDRA 19 subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 4	0 / 29 (0.00%) 0	
ELECTROCARDIOGRAM QT CORRECTED INTERVAL PROLONGED alternative dictionary used: MedDRA 19 subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 29 (0.00%) 0	
PLATELET COUNT DECREASED alternative dictionary used: MedDRA 19 subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 29 (0.00%) 0	
SERUM AMYLASE INCREASED alternative dictionary used: MedDRA 19 subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 29 (0.00%) 0	
THYROID STIMULATING HORMONE INCREASED alternative dictionary used: MedDRA 19 subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 3	0 / 29 (0.00%) 0	
WEIGHT GAIN alternative dictionary used: MedDRA 19			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>WEIGHT LOSS</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>WHITE BLOOD CELL DECREASED</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 27 (18.52%)</p> <p>10</p> <p>13 / 27 (48.15%)</p> <p>32</p> <p>1 / 27 (3.70%)</p> <p>3</p>	<p>2 / 29 (6.90%)</p> <p>5</p> <p>13 / 29 (44.83%)</p> <p>27</p> <p>0 / 29 (0.00%)</p> <p>0</p>	
<p>Injury, poisoning and procedural complications</p> <p>FALL</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>FRACTURE</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>TRACHEAL HEMORRHAGE</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>2</p> <p>1 / 27 (3.70%)</p> <p>1</p> <p>1 / 27 (3.70%)</p> <p>1</p>	<p>0 / 29 (0.00%)</p> <p>0</p> <p>0 / 29 (0.00%)</p> <p>0</p> <p>0 / 29 (0.00%)</p> <p>0</p>	
<p>Cardiac disorders</p> <p>HEART FAILURE</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>VENTRICULAR TACHYCARDIA</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p>	<p>1 / 29 (3.45%)</p> <p>1</p> <p>1 / 29 (3.45%)</p> <p>1</p>	
Nervous system disorders			



DYSGEUSIA		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	4 / 27 (14.81%)	11 / 29 (37.93%)
occurrences (all)	5	14
DYSESTHESIA		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	2	0
DIZZINESS		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)
occurrences (all)	2	1
HEADACHE		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	4 / 27 (14.81%)	4 / 29 (13.79%)
occurrences (all)	12	4
INSTABILITY		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
LETHARGY		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	2 / 27 (7.41%)	1 / 29 (3.45%)
occurrences (all)	10	1
MEMORY IMPAIRMENT		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0
PARESTHESIA		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	3 / 27 (11.11%)	1 / 29 (3.45%)
occurrences (all)	3	1
PERIPHERAL SENSORY NEUROPATHY		
alternative dictionary used: MedDRA 19		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SPINAL CORD COMPRESSION L1</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 27 (11.11%)</p> <p>3</p> <p>1 / 27 (3.70%)</p> <p>1</p>	<p>5 / 29 (17.24%)</p> <p>6</p> <p>0 / 29 (0.00%)</p> <p>0</p>	
<p>Ear and labyrinth disorders</p> <p>HYPERACUSIS</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>VERTIGO</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>1 / 27 (3.70%)</p> <p>1</p>	<p>1 / 29 (3.45%)</p> <p>1</p> <p>0 / 29 (0.00%)</p> <p>0</p>	
<p>Eye disorders</p> <p>BLURRED VISION</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>CATARACT</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>CONJUNCTIVITIS</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>WATERING EYES</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>FLASHING LIGHTS</p> <p>alternative dictionary used: MedDRA 19</p>	<p>1 / 27 (3.70%)</p> <p>2</p> <p>1 / 27 (3.70%)</p> <p>1</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>1 / 27 (3.70%)</p> <p>1</p>	<p>1 / 29 (3.45%)</p> <p>1</p> <p>0 / 29 (0.00%)</p> <p>0</p> <p>1 / 29 (3.45%)</p> <p>1</p> <p>0 / 29 (0.00%)</p> <p>0</p>	

subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
ABDOMINAL PAIN			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	5 / 27 (18.52%)	10 / 29 (34.48%)	
occurrences (all)	5	10	
ANAL ABCES MARGIN			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
ANAL FISTULA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	2	
BLEEDING TOOTH			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
ANAL PAIN			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
BLOATING			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
CHEILITIS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
CONSTIPATION			
alternative dictionary used: MedDRA 19			

subjects affected / exposed	11 / 27 (40.74%)	13 / 29 (44.83%)
occurrences (all)	16	16
DENTAL CARIES		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
DIARRHEA		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	8 / 27 (29.63%)	20 / 29 (68.97%)
occurrences (all)	42	43
DISCHARGING DENTAL SINUS		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	2	0
DRY MOUTH		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	4 / 27 (14.81%)	3 / 29 (10.34%)
occurrences (all)	6	5
DYSPEPSIA		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	2 / 27 (7.41%)	5 / 29 (17.24%)
occurrences (all)	2	5
ESOPHAGITIS		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
EXACERBATION OF GORD		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
FLATULENCE		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0

GASTROINTESTINAL PAIN			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
GASTROESOPHAGEAL REFLUX DISEASE			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	3	
GINGIVAL PAIN			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
GASTROINTESTINAL PERFORATION			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
HEMORRHOIDS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
MUCOCITIS ORAL			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
MUCOSITIS ORAL			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	8 / 27 (29.63%)	12 / 29 (41.38%)	
occurrences (all)	9	19	
ORAL DYSESTHESIA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	2 / 29 (6.90%)	
occurrences (all)	0	2	
NAUSEA			
alternative dictionary used: MedDRA 19			

subjects affected / exposed	9 / 27 (33.33%)	11 / 29 (37.93%)
occurrences (all)	24	13
ORAL HEMORRHAGE		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0
ORAL PAIN		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	4 / 29 (13.79%)
occurrences (all)	1	6
PROCTITIS		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
RECTAL HEMORRHAGE		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0
SMALL INTESTINAL OBSTRUCTION		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
SORE MOUTH		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0
STOMACH PAIN		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)
occurrences (all)	1	1
TOOTHACHE		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)
occurrences (all)	3	1

<p>STOMATITIS</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>1</p>	<p>0 / 29 (0.00%)</p> <p>0</p>	
<p>VOMITING</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>9 / 27 (33.33%)</p> <p>26</p>	<p>5 / 29 (17.24%)</p> <p>8</p>	
<p>Skin and subcutaneous tissue disorders</p> <p>DRY SKIN</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ALOPECIA</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ECZEMA</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ERYTHEMA MULTIFORME</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>HYPERKERATOSIS</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ERYTHRODERMA</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>NAIL RIDGING</p> <p>alternative dictionary used: MedDRA 19</p>	<p>3 / 27 (11.11%)</p> <p>6</p> <p>1 / 27 (3.70%)</p> <p>1</p> <p>1 / 27 (3.70%)</p> <p>1</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>1 / 27 (3.70%)</p> <p>1</p> <p>0 / 27 (0.00%)</p> <p>0</p>	<p>6 / 29 (20.69%)</p> <p>6</p> <p>2 / 29 (6.90%)</p> <p>2</p> <p>0 / 29 (0.00%)</p> <p>0</p> <p>1 / 29 (3.45%)</p> <p>1</p> <p>0 / 29 (0.00%)</p> <p>0</p> <p>1 / 29 (3.45%)</p> <p>3</p>	

subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	8 / 27 (29.63%)	9 / 29 (31.03%)
occurrences (all)	20	19
PRURITIS		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0
RASH ACNEIFORM		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0
RASH		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
PRURITUS		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	2 / 27 (7.41%)	2 / 29 (6.90%)
occurrences (all)	2	2
RASH MACULO-PAPULAR		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	3 / 27 (11.11%)	2 / 29 (6.90%)
occurrences (all)	5	2
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	3 / 29 (10.34%)
occurrences (all)	0	3
SKIN ULCERATION		
alternative dictionary used: MedDRA 19		



subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
SWEAT RASH			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
BLADDER SPASM			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
PERIPHERAL SENSORY NEUROPATHY			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
DYSURIA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
CYSTITIS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
PROTEINURIA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	2 / 29 (6.90%)	
occurrences (all)	1	2	
URINARY RETENTION			
alternative dictionary used: MedDRA 19			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>URINARY URGENCY</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>1</p> <p>1 / 27 (3.70%)</p> <p>1</p>	<p>0 / 29 (0.00%)</p> <p>0</p> <p>0 / 29 (0.00%)</p> <p>0</p>	
<p>Endocrine disorders</p> <p>HYPOTHYROIDISM</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>HYPOTHYROIDISM</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 27 (22.22%)</p> <p>10</p> <p>1 / 27 (3.70%)</p> <p>1</p>	<p>7 / 29 (24.14%)</p> <p>7</p> <p>1 / 29 (3.45%)</p> <p>1</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>ARTHRALGIA</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>BACK PAIN</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>CHEST WALL PAIN</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>FLANK PAIN</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>GENERALIZED MUSCLE WEAKNESS</p> <p>alternative dictionary used: MedDRA 19</p>	<p>3 / 27 (11.11%)</p> <p>3</p> <p>4 / 27 (14.81%)</p> <p>10</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>2 / 27 (7.41%)</p> <p>2</p>	<p>3 / 29 (10.34%)</p> <p>3</p> <p>3 / 29 (10.34%)</p> <p>3</p> <p>1 / 29 (3.45%)</p> <p>1</p> <p>3 / 29 (10.34%)</p> <p>3</p>	

subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
LOWER LIMB MUSCLE CRAMPS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
JOINT RANGE OF MOTION DECREASED			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	1	
HAND AND FEET CRAMPS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)	
occurrences (all)	1	0	
MYALGIA			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	3 / 27 (11.11%)	0 / 29 (0.00%)	
occurrences (all)	3	0	
NECK PAIN			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
OSTEOPOROSIS			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)	
occurrences (all)	0	1	
PAIN IN EXTREMITY			
alternative dictionary used: MedDRA 19			
subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)	
occurrences (all)	1	1	
Infections and infestations			
BRONCHIAL INFECTION			
alternative dictionary used: MedDRA 19			

subjects affected / exposed	1 / 27 (3.70%)	1 / 29 (3.45%)
occurrences (all)	1	1
EYE INFECTION		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
GASTRIC HELICOBACTER PYLORI INFECTION		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
HEAD AND NECK INFECTION		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
INFLUENZA		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0
NAIL INFECTION		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	2 / 27 (7.41%)	0 / 29 (0.00%)
occurrences (all)	2	0
PERIRECTAL ABSCESS		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1
PERITONEAL INFECTION		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	1 / 27 (3.70%)	0 / 29 (0.00%)
occurrences (all)	1	0
STOMATITIS		
alternative dictionary used: MedDRA 19		
subjects affected / exposed	0 / 27 (0.00%)	1 / 29 (3.45%)
occurrences (all)	0	1

<p>TOOTH INFECTION</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p>	<p>2 / 29 (6.90%)</p> <p>3</p>	
<p>URINARY TRACT INFECTION</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 27 (11.11%)</p> <p>3</p>	<p>2 / 29 (6.90%)</p> <p>4</p>	
<p>Metabolism and nutrition disorders</p> <p>ANOREXIA</p> <p>alternative dictionary used: MedDRA 19</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 27 (25.93%)</p> <p>11</p>	<p>10 / 29 (34.48%)</p> <p>13</p>	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 January 2017	This amendment expanded the eligibility criteria of the trial. Initially the trial was limited to High Grade Undifferentiated Uterine Sarcoma (HGUS) and High-Grade Endometrial Stromal Sarcoma (HGESS). The amendment allowed the inclusion of patients with High Grade Leiomyosarcomas (HGLMS) and High Grade adenosarcoma (HGAS).

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/32546554>